S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL

• Steven Knapper,
• Abin Thomas,
• Sophie King,
• Ian Thomas,
• Amanda Gilkes,
• Sarah Irwin,
• Robert Sellar,
• Simone Green,
• Ulrik Malthe Overgaard,
• Priyanka Mehta,
• Mike Dennis,
• Sylvie Freeman,
• Nigel Russell

Affiliations

Steven Knapper

1 Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom

Abin Thomas

2 Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

Sophie King

3 Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

Ian Thomas

3 Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

Amanda Gilkes

4 Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom

Sarah Irwin

5 Cardiff and Vale University Health Board, Cardiff, United Kingdom

Robert Sellar

6 University College Hospital, London, United Kingdom

Simone Green

7 Castle Hill Hospital, Hull, United Kingdom

Ulrik Malthe Overgaard

8 Rigshospitalet, Copenhagen, Denmark

Priyanka Mehta

9 University Hospital of Bristol and Weston NHS Trust, Bristol, United Kingdom

Mike Dennis

10 The Christie NHS Foundation Trust, Manchester, United Kingdom

Sylvie Freeman

11 Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom

Nigel Russell

12 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom